CMV promotes recipient T-cell immunity following reduced-intensity T-cell - Depleted HSCT, significantly modulating chimerism status

Blood

Volumn 125, Issue 4, 2015, Pages 731-739

  Sellar, Rob S ^a,b   Vargas, Frederick Arce ^a   Henry, Jake Y ^a   Verfuerth, Stephanie ^c   Charrot, Sarah ^b   Beaton, Brendan ^c   Chakraverty, Ronjon ^c   Quezada, Sergio A ^a   Mackinnon, Stephen ^c   Thomson, Kirsty J ^b   Peggs, Karl S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CELL COMPARTMENTALIZATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CHIMERA; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DONOR; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; T LYMPHOCYTE; VIRUS IMMUNITY; ALLOGRAFT; CYTOMEGALOVIRUS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE;

ALLOGRAFTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE DEPLETION; MALE; TRANSPLANTATION CHIMERA;

EID: 84921689850     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-589150     Document Type: Article

References (22)

1. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97(5):1232-1240.
2. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78(5):1373-1380.
3. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125-136.
4. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113(25):6465-6476.
5. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;17(4):574-585.
6. Peggs KS, Verfuerth S, Pizzey A, et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant. 2003;9(3):198-205.
7. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934-1941.
8. Thomson KJ, Kayani I, Ardeshna K, et al. A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia. 2013;27(6):1419-1422.
9. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant. 2005;35(2):107-119.
10. Mohamedbhai SG, Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br J Haematol. 2012;156(4):516-522.
11. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2 Pt 1):559-565.
12. Chalandon Y, Degermann S, Villard J, et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood. 2006;107(1):389-396.
13. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113-5123.
14. Hanley PL, Gee A, Leung AP, et al. Multi-Virus-Specific T-Cell Therapy for Patients After Hematopoietic Stem Cell and Cord Blood Transplantation [abstract]. Blood. 2013;122(21). Abstract 140.
15. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958-1967.
16. Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012;(63): e3627.
17. Hanley PJ, Shaffer DR, Cruz CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13(8):976-986.
18. Sili U, Leen AM, Vera JF, et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012;14(1):7-11.
19. McGoldrick SM, Bleakley ME, Guerrero A, et al. Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo. Blood. 2013;121(14):2796-2803.
20. Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD81 cytotoxic T-cell response in natural infection. Blood. 2004;104(4):1075-1082.
21. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD41 and CD81 T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673-685.
22. Khan N, Bruton R, Taylor GS, et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol. 2005; 79(5):2869-2879.